Fig 1.
Study cohort flowchart.
Table 1.
Patient demographics.
Fig 2.
Model-based cumulative incidence (Fine–Gray): escalation to ≥50 MME/day by eGFR category (death as competing event).
Fig 3.
Model-based cumulative incidence (Fine–Gray): escalation to ≥90 MME/day by eGFR category (death as competing event).